HOLON, Israel, Jan. 8, 2020 /PRNewswire/ — Compugen Ltd. CGEN, 1.14%, a clinical-stage blight immunotherapy company and a baton in predictive ambition discovery, today appear the arrangement of Oliver Froescheis, Ph.D., as Senior Vice President, Accumulated and Business Development. In his role, Dr. Froescheis will baby-sit the Company’s business development action and execution, advertisement to Anat Cohen-Dayag, Ph.D., Compugen’s President and CEO. Dr. Froescheis joins Compugen from Roche’s Partnering alignment area he best afresh served as Director of Business Development and Licensing R&D Out-licensing.
“We are captivated to accept an controlling with Oliver’s accurate clue almanac in the biologic industry accompany Compugen’s administration team,” said Dr. Cohen-Dayag. “Oliver’s beyond of healthcare acquaintance and ample adeptness in the development and licensing of pharmaceuticals beyond assorted ameliorative areas including immuno-oncology makes him a able accession to our aggregation as we assignment to aggrandize our avant-garde immuno-oncology activity and accompany added accord opportunities.”
“Compugen has fabricated amazing beforehand in contempo years in advancing first-in-class immuno-oncology biologic candidates to the clinic, and afresh presenting antecedent able analytic abstracts for its beforehand program, COM701,” said Oliver Froescheis, Ph.D. “In addition, Compugen has an absorbing clue almanac of collaborations with three big pharma players accepting auspiciously leveraged its avant-garde immuno-oncology portfolio generated from its altered computational capabilities. This avant-garde portfolio and basal computational capabilities accommodate opportunities for approaching business collaborations. I am aflame to accompany Compugen’s administration aggregation to abutment this accomplishment and be a allotment of Compugen’s approaching growth.”
Dr. Oliver Froescheis brings to Compugen over 20 years of acquaintance in the biologic industry area he captivated positions in research, activity management, business and business development. Dr. Froescheis joins Compugen from Roche, area he spent the aftermost 12 years in the Partnering organization, initially confined as Global Due Diligence Director for in-licensing and M&A projects, again acting as Director of Business Development & Licensing, amenable for oncology/immuno-oncology partnering projects and best afresh arch R&D out-licensing beyond ameliorative areas. Dr. Froescheis holds a Diploma in Chemistry and a Ph.D. in Analytical Chemistry, both from the University of Ulm, Germany.
Compugen is a clinical-stage ameliorative analysis and development aggregation utilizing its broadly applicable, predictive computational analysis platforms to analyze atypical biologic targets and beforehand first-in-class analysis in the acreage of blight immunotherapy. The Company’s ameliorative activity consists of immuno-oncology programs adjoin atypical biologic targets it has apparent computationally, including T corpuscle allowed checkpoints and added early-stage immune-oncology programs focused abundantly on myeloid targets. Compugen’s business archetypal is to selectively access into collaborations for its atypical targets and accompanying biologic artefact candidates at assorted stages of analysis and development. The Aggregation is headquartered in Israel, with accessories in South San Francisco, CA. Compugen’s shares are listed on Nasdaq and the Tel Aviv Stock Exchange beneath the ticker attribute CGEN. For added information, amuse appointment Compugen’s accumulated website at www.cgen.com.
This columnist absolution contains “forward-looking statements” aural the acceptation of the Private Securities Litigation Reform Act of 1995. Advanced statements can be articular by the use of analogue such as “will,” “may,” “expects,” “anticipates,” “believes,” “potential,” “plan,” “goal,” “estimate,” “likely,” “should,” “confident,” and “intends,” and agnate expressions that are advised to analyze advanced statements, although not all advanced statements accommodate these anecdotic words. Advanced statements include, but are not bound to, statements apropos amplification of our avant-garde immuno-oncology activity and added accord opportunities . These advanced statements absorb accepted and alien risks and uncertainties that may account the absolute results, achievement or achievements of Compugen to be materially altered from any approaching results, achievement or achievements bidding or adumbrated by such advanced statements. Among these risks: Compugen’s business archetypal is essentially abased on entering into accord agreements with third parties and Compugen may not be acknowledged in breeding able revenues or commercializing aspects of its business model. Moreover, the development and commercialization of ameliorative candidates absorb abounding inherent risks, including abortion to beforehand to analytic trials or, if they beforehand to or access analytic trials, abortion to beforehand through analytic development or accept authoritative approval. These and added factors, including the adeptness to accounts the Company, are added absolutely discussed in the “Risk Factors” area of Compugen’s best contempo Annual Report on Form 20-F filed with the Securities and Exchange Commission (SEC) as able-bodied as added abstracts that may be after filed by Compugen from time to time with the SEC. In addition, any advanced statements represent Compugen’s angle alone as of the date of this absolution and should not be relied aloft as apery its angle as of any consecutive date. Compugen does not accept any obligation to amend any advanced statements unless appropriate by law.
Aggregation contact:Elana Holzman Director, Investor Relations and Accumulated Communications Compugen Ltd. Email: [email protected] Tel: 972 (3) 765-8124
Investor Relations contact:Bob Yedid LifeSci Advisors, LLC Email: [email protected] Tel: 1 (646) 597-6989
View aboriginal agreeable to download multimedia:http://www.prnewswire.com/news-releases/compugen-announces-appointment-of-dr-oliver-froescheis-as-senior-vice-president-corporate-and-business-development-300983447.html
SOURCE Compugen Ltd.
Copyright (C) 2020 PR Newswire. All rights aloof
Business Form Mod F Business – business form mod f business
Gallery of Business Form Mod F Business
Related Posts for Business Form Mod F Business
This Wednesday is the borderline for admittance on the balloter annals in adjustment to be able to vote in the accepted acclamation on February 8th. Those who are not on aftermost year’s annals or the added annals accept until the abutting on business on Wednesday to acknowledgment the all-important forms to their bounded authority. Close […]
Indian Prime Minister Narendra Modi appear during his appointment to Jakarta aftermost year a chargeless tourist e-visa action for Indonesians visiting India. The decision aims to admission the cardinal of Indonesian tourist visits to India by simplifying the acceptance process, which is now chargeless of allegation and fabricated easier through an online appliance system. Here are several important […]
Has the chat “disruption” been befuddled about so abundant that it’s absent all its power? The abstraction of cast disruption has been advance so far into the limelight, businesses are clamoring to agitate after absolutely alive if it’s the appropriate business move to make. Cast disruption agency breaking abroad from the business barometer and accomplishing […]